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Abstract: Plitidepsin is an antitumor drug of marine origin currently in Phase III clinical 
trials in AGAINST multiple myeloma. In cultured cells, plitidepsin induces cell cycle 
arrest or an acute apoptotic process in which sustained activation of JNK plays a crucial 
role. To optimize its clinical use, we evaluated the possibility of using JNK activation as an 
in vivo biomarker of response. In this study, we show that plitidepsin administration to 
mice xenografted with human cancer cells increases phosphorylation of JNK in tumors at 4 
to 12 h after a single dose of drug. In contrast, no changes were found in other targets of 
plitidepsin in vitro such as the levels of phosphorylated-ERK or -p38MAPK, or of p27KIP1 
protein. Interestingly, plitidepsin also increased JNK phosphorylation in spleens from 
xenografted mice with a similar kinetics to that observed in tumors, suggesting that normal 
tissues might be used to test drug activity. Consistently, the administration of plitidepsin to 
rats that leads to plasma concentrations achievable in patients also increased JNK 
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phosphorylation in peripheral blood mononuclear cells. These data suggest that changes in 
JNK activity is a reliable marker for plitidepsin activity that could be useful to the design 
of clinical trials in order to maximize the efficacy of plitidepsin. 
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1. Introduction 
Plitidepsin (Aplidin®, APL) is a marine cyclic depsipeptide originally isolated from the tunicate 
Aplidium albicans and currently obtained by synthesis. Plitidepsin is under Phase III clinical 
development in patients with relapsed/refractory multiple myeloma (ADMYRE trial). 
Plitidepsin has demonstrated strong anticancer activity in a large variety of human cancer cell lines 
in vitro and in xenografted mice [1]. In cultured cells from solid tumors, plitidepsin induces dose-
dependently cell cycle arrest or an acute apoptotic process mainly through the sustained activation of 
c-Jun N-terminal kinase (JNK) as revealed by an increased level of phosphorylation [2,3]. Plitidepsin 
activates also other kinases such as the epidermal growth factor receptor, protein kinase C-δ and the 
extracellularly regulated and p38 mitogen-activated protein kinases (ERK, p38MAPK) in a cell-
dependent context [4,5]. In breast cancer cells, plitidepsin induces several early response genes such as 
c-JUN, JUNB, JUND, c-FOS, FOSB and FRA1, and also RELA/p65, the major component of the 
transcription factor nuclear factor kappa B (NFkB), while decreases the cellular content of c-MYC 
protein [6]. Additionally, a series of candidate plitidepsin target genes have been identified in 
transcriptomic and proteomic studies in several cell types [7-9]. In sarcoma cells, plitidepsin increases 
the cellular content of the p27KIP1 cell cycle inhibitor [10].  
Plitidepsin has strong activity against hematological cancer cells at nanomolar concentration ranges 
RANGE, in which it activates both the intrinsic/mitochondrial and extrinsic/death receptor apoptotic 
pathways [9,11-13]. Remarkably, plitidepsin-induced apoptosis is only partially dependent of caspases 
and independent of the TP53 tumor suppressor gene status [5,11]. In haematological malignancies 
(myeloma multiple and leukemia) cell lines, plitidepsin induces JNK activation and translocation from 
the cytosol to plasma membrane lipid rafts [9,14]. 
The objective of this study was to identify a potential pharmacodynamic biomarker of plitidepsin. 
In view of the results obtained in a panel of hematological cancer cell lines, we evaluated JNK 
phosphorylation as a surrogate of its activation and a biomarker of plitidepsin activity in vivo. The 
level of JNK phosphorylation was examined in tumors from athymic mice xenografted with human 
leukemia K562 cells following plitidepsin treatment. In K562 tumor-bearing mice, increased 
phosphorylated-JNK level was observed in tumors at 4 to 12 h after a single dose administration. In 
spleens of host mice, a similar time course and extent of phosphorylated-JNK was observed. 
Furthermore, intravenous administration of plitidepsin to rats significantly increased JNK 
phosphorylation in peripheral blood mononuclear cells 8 h after administration. In contrast, no changes 
were found in the levels of phosphorylated-ERK or -p38MAPK. Likewise, the expression of p27KIP1 
was unaffected by plitidepsin. These results validate phosphorylated JNK as a pharmacodynamic 
biomarker of plitidepsin in xenografted tumors as well as in normal surrogate tissues. 




2. Results and Discussion 
2.1. Plitidepsin induces JNK phosphorylation in cultured K562 leukemia and other hematological 
cancer cells  
Previous studies have shown that Plitidepsin induces JNK phosphorylation in a variety of cultured 
solid and hematological cancer cell lines [3-5,9,11,15]. Given the advanced clinical development of 
Plitidepsin in multiple myeloma and leukemia, we evaluated the effect of Plitidepsin on the viability 
and the level of JNK phosphorylation in a panel of these cancer cell types. 
Plitidepsin showed a strong, concentration-dependent effect on the viability of multiple myeloma 
NCI-H929, RPMI8226 and U266B1 cells (IC50 of ~ 11, 13 and 34 nM at 24 h post-treatment) and of 
chronic myelogenous leukemia K562 cells (IC50 of ~ 20 nM) (Fig. 1A). Western blot analysis revealed 
a progressive increase of the level of phosphorylated JNK by plitidepsin in the multiple myeloma cell 
lines, which persisted until cell death (Fig. 1B). In K562 cells, plitidepsin also induced JNK 
phosphorylation that was extremely rapid (within the first 15 min of treatment) and sustained, reaching 
a maximum at 30 to 60 min (Fig. 1B). These results suggested that K562 cells are good responders to 
plitidepsin cytotoxicity and JNK activation and so, a suitable model to assess JNK phosphorylation as 
a potential biomarker of plitidepsin in xenografted mice. An additional reason to choose K562 cells for 
in vivo studies is their expression of the chimeric BCR-ABL protein, which allows checking the purity 
of the tumor and host tissue samples.  
Figure 1. Plitidepsin decreases viability and induces JNK activation in human 
hematological cancer cells. (A) Multiple myeloma NCI-H929, RPMI8226 and U266B1 
cells, and leukemic K562 cells were incubated in the presence of the indicated 
concentrations of plitidepsin (APL) for 24 h and cell viability was determined by the MTT 
assay. Data are mean ± S.E.M. obtained in three experiments performed in quadruplicate.  
(B) Western blot analysis showing the levels of total (JNK) and phosphorylated JNK (P-
JNK) protein in cells incubated with plitidepsin (100 nM) for the indicated times. Actin 
was used as loading control. 
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To optimize the detection of phosphorylated JNK in tissue extracts, we examined by 
immunoprecipitation the specificity of two widely used commercial anti-phospho-JNK antibodies. As 
shown in Supplementary Figure S1, although both antibodies recognized phosphorylated JNK in these 
assays, we selected for the in vivo study the anti-P-JNK sc-6254 antibody from Santa Cruz that 
rendered a better signal in whole protein extracts. 
 
2.2. Plitidepsin induces JNK phosphorylation in both tumors and spleens from K562 xenografts 
To evaluate the ability of plitidepsin to active JNK in vivo we first subcutaneously implanted K562 
cells in athymic nude mice (5 x 106 cells/mouse). Twenty days after initial tumor detection mice were 
randomized into treatment and control groups (five mice/group) and treated animals received 
plitidepsin at 200 µg/kg. Mice in control group were sacrificed immediately after plitidepsin 
administration (0 h). Tumors and spleens of all animals were harvested at several time points after the 
treatment. 
Western blot analysis of JNK phosphorylation in xenografted K562 tumors showed substantial 
variability in each group of animals; however, the number of animals with high level of 
phosphorylated JNK increased in response to 4-12 h plitidepsin treatment (Fig. 2A). No changes in the 
level of total JNK protein were observed. Samples from plitidepsin- or vehicle-treated K562 cells were 
included in each gel in order to compare the signals obtained in different membranes. Quantification of 
phosphorylated JNK upon normalization to total JNK and to differences in inter-membranes signal was 
performed by optical densitometry (Fig. 2B). A tendency for increased level of phosphorylated JNK 
was observed in tumors corresponding to 4 to 12 h plitidepsin administration. This effect was transient, 
as JNK phosphorylation returned to pretreatment levels at 24-48 h after dosing.  
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Figure 2. Plitidepsin increases the level of phosphorylated JNK in tumors of K562-bearing 
mice. Mice xenografted with K562 cells received a single administration of plitidepsin 
(APL; 200 µg/kg) and either immediately (0 min) or at the indicated times after injection 
were sacrificed (5 mice/group). (A) Western blot analysis of total (JNK) and 
phosphorylated JNK (P-JNK) in excised tumors. Actin was used as loading control. K, 
K562 cells; K + APL, plitidepsin-treated K562 cells. (B) Quantification of P-JNK levels 
(normalized to those of total JNK) and related to that of vehicle-treated K562 sample at the 
indicated times after APL administration. Mean ± S.E.M. values of each group of animals 
are shown.  
  
As the phosphorylation of p38MAPK and ERK and the expression level of p27KIP1 protein increase 
in response to plitidepsin in several cultured cell lines [4,5,10], we examined also the activation of 
these kinases and p27KIP1 level by using appropriate antibodies. In contrast to the in vitro data, 
plitidepsin did not change the level of phosphorylated-ERK or -p38MAPK in xenografted K562 
tumors (Supplementary Fig. S2). This result discarded these kinases as markers of plitidepsin action in 
vivo. Likewise, no changes were found in the level of p27KIP1 expression following plitidepsin 
administration (Supplementary Fig. S3). Confirming the purity of excised tumors, high level of the 
fusion BCR-ABL protein expressed in the xenografted K562 cells was found in tumor samples 
(Supplementary Fig. S4). 
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We then sought to compare phosphorylation of JNK in tumor and normal tissues that might be used 
as a surrogate to analyze changes in level of phosphorylated JNK in response to plitidepsin. For that 
purpose we chose spleens that are a source of mononuclear cells. Interestingly, JNK phosphorylation 
increased in spleens from K562 tumor-bearing mice after plitidepsin administration (Fig. 3A). 
Moreover, both tissues responded similarly to plitidepsin treatment and there was a good correlation 
between the levels of phosphorylated JNK is tumor and spleen in each animal (Fig. 3A). Consistently 
with the previous experiment, densitometry analysis confirmed an increase of phosphorylated JNK in 
spleens of mice treated with plitidepsin for 4 to 12 hours, an effect that reversed also at 24 h post-
treatment (Fig. 3B).  
Figure 3. Plitidepsin increases the level of phosphorylated JNK in spleens of K562 tumor-
bearing mice. Mice xenografted with K562 cells received a single administration of 
plitidepsin (APL; 200 µg/kg) and either immediately (0 min) or at the indicated times after 
injection were sacrificed (5 mice/group). (A) Western blot analysis of total (JNK) and 
phosphorylated JNK (P-JNK) in spleens excised from the animals. Actin was used as 
loading control. K, K562 cells; K + APL, plitidepsin-treated K562 cells. (B) Quantification 
of P-JNK levels (normalized to those of total JNK) at the indicated times after APL 
administration and related to that of sample vehicle-treated K562 at the indicated times 
after APL administration. Mean ± S.E.M. values of each group of animals are shown.  
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To confirm JNK phosphorylation as a pharmacodynamic biomarker of plitidepsin allowing a better 
statistical analysis, we performed a new experiment using higher number of animals per group. Fifteen 
K562 tumor-bearing mice were treated with a single dose of plitidepsin (200 µg/kg) for 0, 8, 12, or 24 
h, and the level of phosphorylated JNK was analyzed in tumors and spleens by Western blot. To allow 
the comparison of signals in different membranes, samples from four untreated mice were included in 
all of them. Confirming earlier observations, a transient increase in JNK phosphorylation was found in 
response to plitidepsin in both, tumors and spleens from xenografted mice (Supplementary Fig. S5). In 
addition, to include all data in the statistical analysis, samples from the first experiment were analyzed 
together with control samples from the second one (Supplementary Fig. S6). For statistics evaluation, 
signals were quantified by densitometry and related to that of control sample #64, which was selected 
as reference signal. A strong correlation was found between the increase in JNK phosphorylation in 
tumors and spleens of the same animal, with a Spearman´s correlation coefficient of 0.73 and a P value 
< 0.0001 (Fig. 4A). In addition, a statistically significant increase in phosphorylated JNK was found at 
8 h after plitidepsin treatment in spleens (P value = 0.009) (Fig. 4B) and a strong tendency close to 
significance in tumors (P value = 0.066) (Fig. 4C). In summary, these data demonstrated that JNK is 
activated in response to plitidepsin in vivo and suggested that JNK activation can be detected in both, 
tumors and normal mouse tissues. 
Figure 4. Statistical analysis of JNK activation by plitidepsin in tumors and spleens from 
mice xenografted with K562 leukemia cells. (A) Relation between the activation of JNK in 
tumors and spleens of K562 bearing-mice after plitidepsin administration. Samples 
corresponding to mice untreated and treated with plitidepsin (200 µg/kg) for 0, 8, 12 or 24 
h were pooled. p-JNK/total JNK ratios in tumors and spleens were computed and their 
correlation statistically assessed following a non-parametric approach. The Spearman´s 
correlation coefficient (r) and P value are shown. (B, C) Box-plot of JNK activation in 
tumors and spleens of K562 bearing-mice after plitidepsin administration. The p-JNK/JNK 
ratio in spleens (B) and tumors (C) at each time point was compared to that of mice that 
were sacrificed just after plitidepsin injection (0 h) using Wilcoxon rank-sum test. A box-
plot of JNK activation in each group (18-20 mice/group) and its statistical significance (p) 
are presented. Boxes in the plot include values in the 25%-75% interval; internal lines 
represent the median. 




2.3. Plitidepsin induces JNK phosphorylation in peripheral blood mononuclear cells 
As the spleen is not an achievable tissue in humans for regular pharmacodynamic biomarker 
measurement, we next decided to determine whether plitidepsin could also affect JNK phosphorylation 
of mononuclear cells (PBMCs) in peripheral blood of healthy animals. To this end, PBMCs were 
prepared from healthy rats following a single intravenous administration of plitidepsin (1 mg/kg), 
which yielded plasma concentrations of around 2 ng/mL that are similar to those achieved in clinical 
trials [16,17] (Supplementary Table S1). As above, the levels of total and phosphorylated JNK were 
examined by Western blot. In order to improve quantification accuracy, we used the Odyssey Infrared 
Imaging System (Li-Cor Biosciences). In an initial time course analysis, we found a tendency for 
increased phosphorylated JNK in PBMCs at all post-treatment times studied (Fig. 5). 
Figure 5. Plitidepsin increases JNK phosphorylation in rat peripheral blood mononuclear 
cells. (A) Blood mononuclear cells (PBMCs) were isolated from non-tumor-bearing rats 
after 4, 8 and 24 h i.v. administration of plitidepsin (1 mg/kg) and the levels of total (JNK) 
and phosphorylated JNK (P-JNK) were analysed by Western blot. Control group were 
treated only with vehicle (control (0 h)). Actin was used as loading control for 
normalization. Immunoblots were incubated with infrared-labeled secondary antibodies, 
and the signals were visualized and quantified using the Odyssey Infrared Imaging System 
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(Li-Cor Biosciences). (B) Quantification of P-JNK/JNK ratio upon normalization to actin 
level at the indicated times after plitidepsin administration in PBMCs derived from non-
tumor-bearing rats. Mean ± S.E.M. values of each group of animals are shown. 
 
To allow a statistical analysis with higher number of animals studied, we performed a new 
experiment at 8 h of plitidepsin administration. As shown in Figure 6A, plitidepsin increased the level 
of JNK phosphorylation in PBMCs at 8 h after administration. No significant changes in the level of 
total JNK protein were observed. Quantitative analysis using Odyssey software revealed a highly 
significant statistical increase in JNK phosphorylation (P = 0.005) in PBMCs of rats 8 h after a single 
administration of plitidepsin (Fig. 6B). This effect parallels the increase of JNK phosphorylation found 
in tumors and tissues of xenografted mice (Fig. 4). Together, these data support the notion that 
phosphorylated JNK may serve as a pharmacodynamic marker for plitidepsin activity and suggest that 
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changes in JNK activity in PBMCs could perhaps be used as a biomarker when assessing plitidepsin 
treatment schedules in clinical trials. 
Figure 6. Plitidepsin induces a statistically significant increase of the level of 
phosphorylated JNK in PBMCs of healthy rats after 8 hours of administration. (A) Western 
blot analysis of JNK and P-JNK proteins in PBMCs obtained from rats treated with 
plitidepsin (1 mg/kg) for 8 h. Actin was used as loading control. Immunoblots were 
incubated with infrared-labeled secondary antibodies, and the signals were visualized and 
quantified using the Odyssey Infrared Imaging System (Li-Cor Biosciences). (B) Statistical 
analysis of JNK activation in PBMCs obtained from rats at 8 h after plitidepsin 
administration. Comparison between the P-JNK/JNK ratio in PBMCs of rats treated with 
plitidepsin or vehicle for 8 h using the Wilcoxon rank-sum test. A box-plot of JNK 
activation in each group (15-18 mice/group) and its statistical significance using Wilcoxon 
rank-sum test (p) are presented. Boxes in the plot include values in the 25%-75% interval; 
internal lines represent the median.  
 
2.4. Discussion 
In this study we demonstrate that plitidepsin suppresses cell proliferation in a panel of 
hematological cancer cell lines with an IC50 in the nanomolar range, confirming its anti-tumor activity 
[1]. This growth inhibition is accompanied by a sustained activation of JNK that, together with data 
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obtained in other cultured cells [3-5,9,11,15], led us to investigate JNK as a potential surrogate marker 
for plitidepsin activity. In agreement with this hypothesis, we found that plitidepsin increases the level 
of phosphorylated JNK in vivo, both in xenografted tumors generated by human leukemia K562 cells 
in immunodeficient mice and in the spleens of host animals. Importantly, the effect of JNK in tumors 
and spleens parallels and is concomitant. Although this does not ensure an equal effect against tumor 
or toxicity against a surrogate tissue, it supports that the drug concentration used is appropriate to 
induce a robust biological response in the host animals.  
Our data show that plitidepsin treatment that leads to plasma concentrations achieved in cancer 
patients also increases JNK phosphorylation in PBMCs of healthy rats. This finding further suggests 
that normal tissues can be reliable markers of plitidepsin activity in vivo. This observation is 
particularly relevant because obtaining tumor biopsies is not usually feasible in patients, and the use of 
human PBMCs preparation allows sequential sampling for assessing plitidepsin treatment schedules in 
the clinical setting. Our data showing that JNK activation upon plitidepsin administration might be 
used in vivo as a biomarker of response is consistent with the evidence that JNK is a protein critical for 
the anti-tumor activity of plitidepsin in vitro [6]. 
The mitogen-activated protein kinase pathway is a well accepted target for cancer therapy. 
Although JNK is implicated in oncogenic transformation and tumorigenesis due to its known ability to 
promote proliferation, a large number of studies have also linked JNK to tumor suppression. One 
mechanism of tumor suppression is mediated by the pro-apoptotic effects of JNK activation [18,19]. It 
seems that the extent and/or duration of activation of JNK is important to determine the cellular 
response; extent or long activation leads to apoptosis, whereas low or transient activation leads to cell 
growth and differentiation [20]. Phosphorylation of JNK at residues (Thr183, Tyr185) that are recognized 
by the antibodies used in this study is linked to the activation of this enzyme and to the induction of 
apoptosis in many systems [21,22]. In cultured cells, sustained activation (hours) of JNK, but not 
transient (minutes), causes apoptosis in response to diverse stimuli that include anti-tumor drugs in 
clinical use [23,24]. Thus, cisplatin, 5-fluorouracil, etoposide, vinblastine and paclitaxel, among others, 
increase JNK phosphorylation in different human cancer cell types [25-29]. In our in vivo system the 
increase in JNK phosphorylation was first detected a few hours after administration of plitidepsin to 
mice and lasted for at least 8 h to then decline to basal level. Although temporal correlations between 
in vitro and in vivo systems are difficult, this kinetics may be considered a sustained activation of JNK. 
Notably, at least in human melanoma cells JNK mediates both dose-dependent plitidepsin-induced cell 
cycle arrest and apoptosis [3]. 
In contrast to JNK, the kinases p38MAPK and ERK, and the cell cycle inhibitor p27KIP1 that had 
been shown to be targets of plitidepsin in several cultured cell types did not response to administration 
of the drug in vivo in our studies. This could be due to differences in cell specificity and/or to the in 
vitro conditions (culture media, plastic dishes…). Alternatively or additionally, changes in p38MAPK, 
ERK and p27KIP1 by plitidepsin may require higher doses and/or longer times.  
Clearly, the identification of biomarkers of response in preclinical models is essential to the clinical 
development of novel drugs. In the clinic, biomarkers may help to identify the optimal dose and 
regimen, predict and monitor drug sensitivity, and select patients most likely to respond to a 
therapeutic agent. Indeed, extensive preclinical biomarker studies have facilitate the development of 
numerous anticancer agents that have undergone clinical evaluation, including imatinib (Gleevev), 
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trastuzumab (Herceptin), gefitinib (Iressa), sunitinib malate (Sutent), dasatinib (Sprycel) and 
everolimus (Afintor)  [30-37]. Plitidepsin has successfully advanced to Phase II/III clinical trials for 
the treatment of hematological malignancies [38] (ADMYRE trial), but molecular targets that predict 
its response have not been identified yet. In this report, we show that plitidepsin suppresses the 
proliferation of cultured hematological cancer cells in parallel with a sustained activation of JNK, a 
protein associated with cancer. Importantly, plitidepsin induces the phosphorylation of JNK in vivo and 
support the potential use of phosphorylated JNK as a pharmacodynamic biomarker to predict and 
monitor drug sensitivity in cancer patients. Furthermore, the results obtained show that phosphorylated 
JNK in spleens and in PBMCs is a reliable surrogate for phosphorylated JNK in tumors, and suggest 
that JNK activation by plitidepsin can be detected in normal tissues. Therefore, blood sampling could 
provide a source of material for biomarker evaluation of plitidepsin in the clinic.  
3. Experimental Section  
3.1. Cell culture and drug solutions 
 
Human K562 chronic myelogenous leukemia, and RPMI8226, U266B1 and NCI-H929 multiple 
myeloma cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and 
cultured in RPMI 1640 medium supplemented with 10% FCS and penicillin and streptomycin (all 
from GIBCO-Invitrogen, Paisley, UK). For tumor implantation, K562 cells obtained directly from the 
in vitro culture were suspended in 50% Matrigel®/RPMI 1640 media without serum or antibiotics. 
Passage 17 cells were implanted into the mice. Plitidepsin (Aplidin®, APL) was obtained from 
PharmaMar (Madrid, Spain). Stock solutions were freshly prepared in dimethylsulfoxide (DMSO). For 
in vivo studies, lyophilized vials of plitidepsin were reconstituted with vehicle 
(cremophor/ethanol/water) and further dissolved in PBS to reach the target dose. 
 
3.2. Cell proliferation analysis 
 
Cell proliferation was studied by [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl] tetrazolium bromide 
(MTT) assays that were performed following the manufacturer’s instructions (MTT Cell Proliferation 
Kit I, Roche Diagnostics, Mannheim, Germany). 
 
3.3. Xenograft tissues studies 
 
For the generation of K562 leukemia xenografts, we used 12 to 13 week-old (18-24 g) female 
athymic nude mice (Harlan, Madison, WI, USA). Mice were house in ventilated racks and provided 
with irradiated food and sterilized water ad libitum. On Day 1, mice were implanted with 5 x 106 K562 
cells per mouse subcutaneously. Tumor size measurements were recorded twice weekly beginning on 
Day 5 using vernier calipers. The formula to calculate volume for a prolate ellipsoid was used to 
estimate tumor volume from 2-dimentional tumor measurements: tumor volume (mm3) = (length x 
width2) ÷ 2.  On Day 20, tumors reached an average volume of 532.8 mm3 ± 125.1 (mean ± SD) and 
mice were randomized into treatment and control groups. Treatments were initiated and administered 
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on an individual body weight basis. Animals received a single bolus intraperitoneal dose of plitidepsin 
at 200 µg/kg and dosed at a volume of 10 mL/kg. Control groups were treated with vehicle alone. 
Then, at 0.5, 0.75, 1, 2, 4, 8, 12, 24, and 48 h post-dosing, mice were CO2 euthanized and 
exsanguinated via cardiac puncture. Tumors and spleens were harvested from each animal, 
individually identified and stored at -80oC until further processed. 
All animal protocols were reviewed and approved according to regional Institutional Animal Care 
and Use Committees. 
 
3.4. Protein lysates from cells and in vivo tissues 
 
Total protein extracts from cultured cell were prepared as described elsewhere [3,6]. To obtain 
protein lysates from mouse tissues (tumors and spleens) collected at various time points after dosing, 
samples were fragmented and pulverized in liquid nitrogen using a mortar. The resultant powder was 
transferred into a Potter-Elvehjem and homogenized with chilled lysis buffer (50 mM Tris-HCl (pH 
7.5), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 2 mM MgCl2, 1 mM EDTA, 10% 
glycerol, 100 µg/ml PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 30 nM GM6001 MMP inhibitor, 1 
mM Na3VO4, 1 mM NaF, 10 mM β-glycerolphosphate and 0.5 mM DTT). Homogenates were 
centrifuged at 14,000 g at 4ºC for 20 min and the supernatants were transferred to new tubes. Protein 
extracts were quantified using the DC Protein Assay Kit (Bio-Rad). To obtain peripheral blood 
mononuclear cells (PBMCs) from rats treated with plitidepsin, Sprague Dawley male rats (Harlan) 
received a single bolus dose of either plitidepsin (1 mg/kg) or placebo. Blood samples were collected 
at 4, 8 and 24 hours post-dosing by cardiac puncture from deeply isofluorane-anesthetized animals. 
The blood was transferred into BD Vacutainer® CPT Mononuclear Cell Preparation Tubes (Becton 
Dickinson) and processed according to Manufacturer`s instructions. After the centrifugation (1,800 g, 
20 min, 25ºC), lymphocytes portion was isolated and cell pellets were resuspended in complete lysis 
buffer and processed for JNK expression as described for mouse tissues. The resulting plasma samples 
were aliquoted and frozen at -80ºC until bioanalysis. Plitidepsin quantification was performed by a 
sensitive LC/MS-MS method previously described [39]. 
        
3.5. Western blot analysis 
 
Twenty µg protein were subjected to SDS-PAGE and transferred to PVDF membranes. Membranes 
were blocked at room temperature for 1 h in TBS-T (20 mM Tris pH 7.4, 136 mM NaCl, 0.1% Tween-
20) containing 5% bovine albumin and incubated overnight at 4ºC with the appropriated antibody. 
Antibodies used were: anti-phosphorylated-JNK (sc-6254), anti-JNK (sc-474), anti-p38MAPK (sc-
535), anti-phosphorylated-ERK (sc-7383), anti-ERK (sc-154) and anti-p27KIP1 (sc-776) from Santa 
Cruz Biotechnology, anti-phospho-JNK (#9251) and anti-phosphorylated-p38MAPK (#9211) from 
Cell Signaling and anti-c-Abl (Ab-3) from Calbiochem. Alexa-Fluor anti-mouse 680, Alexa-Fluor anti-
rabbit 680 and Alexa-Fluor anti-goat 800 were from Li-Cor Bioscience. HPR-conjugated anti-mouse 
IgG (H+L) was from Promega, and HPR-conjugated anti-rabbit IgG (H+L) from MP Biomedicals. As 
a loading control, membranes were re-probed for actin (sc-1616) provided by Santa Cruz 
Biotechnology. After washing, blots were incubated with HPR-labeled or infrared-labeled secondary 
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antibodies for 1 h at room temperature and developed by a peroxidase reaction using the ECL 
detection system (Amersham-G.E. Healthcare) or visualized using the Odyssey Infrared Imaging 
System (Li-Cor Biosciences, Lincoln, NE, USA). 
Immunoprecipitation of JNK was conducted by incubating 500 µg of protein extracts from tumors 
with 1 µg of the following antibodies: anti-JNK (sc-474) from Santa Cruz Biotechnology and anti-
phosphorylated-JNK (#9251) from Cell Signaling, and collected on Gammabind-Sepharose beads 
(Amersham-Pharmacia Biotech). Immunoprecipitated proteins were separated by SDS-PAGE and 
subjected to immunoblot analysis using anti-phosphorylated-JNK (#9251) from Cell Signaling or anti-
phosphorylated-JNK (sc-6254) from Santa Cruz Biotechnology. 
 
3.6. Statistical Analysis   
 
Overall differences in JNK expression at different times in the same tissue were evaluated using 
Kruskal Wallis test. Two-by-two comparisons were also performed using Wilcoxon rank-sum test and 
taken the expression at time 0, that is, at the moment of plitidepsin injection, as reference. Correlation 
between the level of phosphorylated JNK measured in matched tumor and spleen samples from the 
same animal was assessed by computing the Spearman’s coefficient and its statistical significance. The 
data were analysed by using STATA software (StataCorp LP, College Station TX). 
4. Conclusions  
Plitidepsin increases JNK phosphorylation in xenografted tumors and in surrogate rodent tissues. 
Our data support that phosphorylated-JNK may serve as a reliable marker for plitidepsin activity and 
suggest that changes in JNK activity of peripheral blood cells could be used as a pharmacodynamic 
marker for this agent. 
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Figure S1. Specificity of antibodies against phosphorylated JNK. JNK protein was 
immunoprecipitated from tumor extracts (#2.1 and #7.1; see Figure 2) using either anti-
JNK antibody (sc-474, Santa Cruz; IP-1) or anti-P-JNK (#9251, Cell Signaling; IP-2). Two 
aliquots of each immunoprecipitate were subjected to SDS-PAGE followed by 
immunoblotting using anti-P-JNK sc-6254 antibody from Santa Cruz (panel A) or anti-P-
JNK #9251 from Cell Signaling (panel B). For comparison, overexposed images are shown 
(low in both panels) to detect the signal in whole protein extracts. 
   
Figure S2. Levels of phosphorylated-p38MAPK and phosphorylated-ERK in 
xenografted tumors after plitidepsin treatment. K562 tumor-bearing mice were treated 
with plitidepsin (200 µg/kg) for the indicated times and tumors were excised, processed, 
and subjected to immunoblot analysis for total (p38) and phosphorylated p38MAPK 
protein (P-p38) and total (ERK) and phosphorylated ERK protein (P-ERK).  
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Figure S3. Levels of p27KIP1 in tumors of K562-bearing mice after plitidepsin 
treatment. K562 xenografted mice were treated with plitidepsin (200 µg/kg) for the 
indicated times and tumors were excised, processed, and subjected to immunoblot analysis 
for p27KIP1. Actin was used as loading control. 
   
Figure S4. Levels of c-Abl and BCR-ABL proteins in tumors from mice xenografted 
with K562 cells. Western blot analysis of the expression of c-Abl and BCR-ABL 
(Bcr/Abl) proteins in tumors excised from mice xenografted with K562 cells that were 
treated with plitidepsin (200 µg/kg) for the indicated times. K, K562 cells; K + APL, 
plitidepsin-treated K562 cells. 
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Figure S5. Levels of phosphorylated JNK in tumors and spleens of K562 tumor-
bearing mice after plitidepsin treatment. Tumors (A) and spleens (B) from plitidepsin-
treated xenografted mice (study #2) were excised, processed and subjected to Western blot 
analysis of total (JNK) and phosphorylated JNK (P-JNK). Actin was used as loading 
control. Values (Arbitrary Units, A.U.) correspond to P-JNK/JNK ratio in each sample 
normalized to actin and related to the same ratio in control sample #64. 
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Figure S6. Levels of phosphorylated JNK in tumors and spleens from mice 
xenografted with human K562 leukemia cells after plitidepsin administration. Tumors 
(A) and spleens (B) from plitidepsin-treated xenografted mice (study #1; see Figure 2) 
were excised, processed and subjected to Western blot analysis of JNK and P-JNK together 
with control samples from study #2. Actin was used as loading control. Values (Arbitrary 
Units, A.U.) correspond to P-JNK/JNK ratio in each sample normalized to actin and related 
to the same ratio in control sample #64. 
 
Table S1. Levels of plitidepsin in plasma from healthy rats after plitidepsin 
administration. Blood was isolated from non-tumor-bearing rats after 8 h i.v. 
administration of plitidepsin (1 mg/kg) (APL group; #APL1-10) or vehicle (control group; 
#C1-10), and the levels of plitidepsin in plasma were measured by a sensitive LC/MS-MS 
method [39]. Undetected; below limit of quantification, 0.05 ng/mL.  
 
 
